Anthony P. Conley, MD

Peer-Reviewed Articles

1. Parkes A, Wang WL, Patel S, Leung CH, Lin H, Conley AP, Somaiah N, Araujo DM, Zarzour M, Livingston JA, Ludwig J, Roland CL, Ravi V, Benjamin RS, Ratan R. Outcomes of systemic therapy in metastatic phyllodes tumor of the breast. Breast Cancer Res Treat 186(3):871-882, 2021. e-Pub 2021. PMID: 33575859.
2. Paz-Ares L, Barlesi F, Siena S, Ahn MJ, Drilon A, Conley A, Rolfo C, Wolf J, Seto T, Doebele R, Kapre A, Chen D, McCallum S, Osborne S, Demetri G. Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours. ESMO Open 6(3):100113. e-Pub 2021. PMID: 33930659.
3. Tsai JW, Leung CH, Lin H, Ingram D, Khan S, Wani K, Conley AP, Rhines LD, Lazar AJ, Wang WL. Immune microenvironment in chordoma. Modern Pathology, 2021.
4. Groisberg R, Roszik J, Conley AP, Lazar AJ, Portal DE, Hong DS, Naing A, Herzog CE, Somaiah N, Zarzour MA, Patel S, Brown RE, Subbiah V. Genomics, morphoproteomics, and treatment patterns of alveolar soft part sarcoma patients and response to multiple experimental therapies. Mol Cancer Ther 19(5):1165-1172, 2020. e-Pub 2020. PMID: 32127467.
5. Wu CC, Beird HC, Andrew Livingston J, Advani S, Mitra A, Cao S, Reuben A, Ingram D, Wang WL, Ju Z, Hong Leung C, Lin H, Zheng Y, Roszik J, Wang W, Patel S, Benjamin RS, Somaiah N, Conley AP, Mills GB, Hwu P, Gorlick R, Lazar A, Daw NC, Lewis V, Futreal PA. Immuno-genomic landscape of osteosarcoma. Nat Commun 11(1):1008, 2020. e-Pub 2020. PMID: 32081846.
6. Kairemo K, Santos EB, Macapinlac HA, Patel S, Conley AP, Hong DS, Subbiah AV. Molecular Imaging with 3'-deoxy-3'[(18)F]-Fluorothymidine (18F-FLT) PET/CT for Early Response to Targeted Therapies in Sarcomas: A Pilot Study. Diagnostics (Basel) 10(3), 2020. e-Pub 2020. PMID: 32106426.
7. Raza SM, Habib A, Wang WL, Gildey PW, Conley AP, Nader ME, Hanna EY, Su SY, DeMonte F. Surgical Management of Primary Skull Base Osteosarcomas: Impact of Margin Status and Patterns of Relapse. Neurosurgery 86(1):E23-E32, 2020. e-Pub 2019. PMID: 31515560.
8. Ali AMR, Tsai JW, Leung CH, Lin H, Ravi V, Conley AP, Lazar AJ, Wang WL, Nathenson MJ. The immune microenvironment of uterine adenosarcomas. Clin Sarcoma Res 10:5, 2020. e-Pub 2020. PMID: 32231779.
9. Parkes A, Urquiola E, Bhosale P, Lin H, Watson K, Wang WL, Feig B, Torres K, Roland CL, Conley AP, Zarzour M, Livingston JA, Ratan R, Ludwig J, Araujo DM, Ravi V, Benjamin RS, Patel S, Somaiah N. PET/CT Imaging as a Diagnostic Tool in Distinguishing Well-Differentiated versus Dedifferentiated Liposarcoma. Sarcoma 2020:8363986, 2020. e-Pub 2020. PMID: 32565716.
10. Dupuis M, Shen Y, Curcio C, Meis JM, Wang WL, Amini B, Rhines L, Reuther J, Roy A, Fisher KE, Conley AP, Andrew Livingston J. Successful treatment of lipofibromatosis-like neural tumor of the lumbar spine with an NTRK-fusion inhibitor. Clin Sarcoma Res 10:14, 2020. e-Pub 2020. PMID: 32782782.
11. Joseph J, Nathenson MJ, Trinh VA, Malik K, Nowell E, Carter K, Weathers SP, Demetri GD, Araujo D, Conley AP. Guillain-Barre syndrome observed with adoptive transfer of lymphocytes genetically engineered with an NY-ESO-1 reactive T-cell receptor. J Immunother Cancer 7(1):296, 2019. e-Pub 2019. PMID: 31703609.
12. Bishop AJ, Bird JE, Conley AP, Roland CL, Moon BS, Satcher RL, Livingston JA, Patel S, Wang WL, Lazar AJ, Lewis VO, Lin PP, Guadagnolo BA. Extraskeletal Myxoid Chondrosarcomas: Combined Modality Therapy With Both Radiation and Surgery Improves Local Control. Am J Clin Oncol 42(10):744-748, 2019. e-Pub 2019. PMID: 31436747.
13. Roszik J, Khan A, Conley AP, Livingston JA, Groisberg R, Ravi V, Carmagnani Pestana R, Sen S, Subbiah V. Unique Aberrations in Intimal Sarcoma Identified by Next-Generation Sequencing as Potential Therapy Targets. Cancers (Basel) 11(9), 2019. e-Pub 2019. PMID: 31480474.
14. Conley AP, Wang WL, Livingston JA, Ravi V, Tsai JW, Ali A, Ingram DR, Lowery CD, Roland CL, Somaiah N, Hwu P, Yee C, Subbiah V, Futreal A, Lazar AJ, Patel S, Roszik J. MAGE-A3 is a clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma. Cancers (Basel) 11(67):1-10, 2019. e-Pub 2019. PMID: 31096717.
15. Bhatty M, Kato S, Piha-Paul SA, Naing A, Subbiah V, Huang HJ, Karp DD, Tsimberidou AM, Zinner RG, Hwu WJ, Javle M, Patel SP, Hu MI, Varadhachary GR, Conley AP, Ramzanali NM, Holley VR, Kurzrock R, Meric-Bernstam F, Kwang Chae Y, Kim KB, Falchook GS, Janku F. Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients With BRAF-mutated melanoma and other advanced malignancies. Cancer 125(3):463-472, 2019. e-Pub 2018. PMID: 30383888.
16. D'Souza MP, Adams E, Altman JD, Birnbaum ME, Boggiano C, Casorati G, Chien YH, Conley A, Eckle SBG, Früh K, Gondré-Lewis T, Hassan N, Huang H, Jayashankar L, Kasmar AG, Kunwar N, Lavelle J, Lewinsohn DM, Moody B, Picker L, Ramachandra L, Shastri N, Parham P, McMichael AJ, Yewdell JW. Casting a wider net: Immunosurveillance by nonclassical MHC molecules. PLoS Pathog 15(2):e1007567, 2019. e-Pub 2019. PMID: 30789961.
17. van Maldegem A, Conley AP, Rutkowski P, Patel SR, Lugowska I, Desar IME, Bovée JVMG, Gelderblom H. Outcome of First-Line Systemic Treatment for Unresectable Conventional, Dedifferentiated, Mesenchymal, and Clear Cell Chondrosarcoma. Oncologist 24(1):110-116, 2019. e-Pub 2018. PMID: 30082492.
18. Gianni M, Qin Y, Wenes G, Bandstra B, Conley AP, Subbiah V, Leibowitz-Amit R, Ekmekcioglu S, Grimm EA, Roszik J. High-Throughput Architecture for Discovering Combination Cancer Therapeutics. JCO Clin Cancer Inform 2:1-12, 2018. PMID: 30652536.
19. Shewale JB, Mitchell KG, Nelson DB, Conley AP, Rice DC, Antonoff MB, Hofstetter WL, Walsh GL, Swisher SG, Roth JA, Mehran RJ, Vaporciyan AA, Weissferdt A, Sepesi B. Predictors of survival after resection of primary sarcomas of the chest wall-A large, single-institution series. J Surg Oncol 118(3):518-524, 2018. e-Pub 2018. PMID: 30109699.
20. Nathenson MJ, Conley AP, Lin H, Fleming N, Lazar A, Wang WL, Ravi V. The Importance of Lymphovascular Invasion in Uterine Adenosarcomas: Analysis of Clinical, Prognostic, and Treatment Outcomes. Int J Gynecol Cancer 28(7):1297-1310, 2018. PMID: 30044322.
21. Conley AP, Trinh VA, Zobniw CM, Posey K, Martinez JD, Arrieta OG, Wang WL, Lazar AJ, Somaiah N, Roszik J, Patel SR. Positive Tumor Response to Combined Checkpoint Inhibitors in a Patient With Refractory Alveolar Soft Part Sarcoma: A Case Report. J Glob Oncol 4(4):1-6, 2018. e-Pub 2017. PMID: 30241159.
22. Subbiah V, Murthy R, Hong DS, Prins RM, Hosing C, Hendricks K, Kolli D, Noffsinger L, Brown R, McGuire M, Fu S, Piha-Paul S, Naing A, Conley AP, Benjamin RS, Kaur I, Bosch ML. Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers. Clin Cancer Res 24(16):3845-3856, 2018. e-Pub 2018. PMID: 30018119.
23. Somaiah N, Beird HC, Barbo A, Song J, Mills Shaw KR, Wang WL, Eterovic K, Chen K, Lazar A, Conley AP, Ravi V, Hwu P, Futreal A, Simon G, Meric-Bernstam F, Hong D. Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations. Oncotarget 9(28):19891-19899, 2018. e-Pub 2018. PMID: 29731991.
24. Nathenson MJ, Conley AP, Sausville E. Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas. Oncologist 23(1):71-83, 2018. e-Pub 2017. PMID: 28935774.
25. Groisberg R, Hong DS, Behrang A, Hess K, Janku F, Piha-Paul S, Naing A, Fu S, Benjamin R, Patel S, Somaiah N, Conley A, Meric-Bernstam F, Subbiah V. Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. J Immunother Cancer 5(1):100, 2017. e-Pub 2017. PMID: 29254498.
26. Wagner MJ, Gopalakrishnan V, Ravi V, Livingston JA, Conley AP, Araujo D, Somaiah N, Zarzour MA, Ratan R, Wang WL, Patel SR, Lazar A, Ludwig JA, Benjamin RS. Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults. Oncologist 22(10):1271-1277, 2017. e-Pub 2017. PMID: 28710342.
27. Reddy N, Moudgil R, Lopez-Mattei JC, Karimzad K, Mouhayar EN, Somaiah N, Conley AP, Patel S, Giza DE, Iliescu C. Progressive and Reversible Conduction Disease With Checkpoint Inhibitors. Can J Cardiol 33(10):1335.e13-1335.e15, 2017. e-Pub 2017. PMID: 28822650.
28. Groisberg R, Roszik J, Conley A, Patel SR, Subbiah V. The Role of Next-Generation Sequencing in Sarcomas: Evolution From Light Microscope to Molecular Microscope. Curr Oncol Rep 19(12):78, 2017. e-Pub 2017. PMID: 29030741.
29. Livingston JA, Bugano D, Barbo A, Lin H, Madewell J, Wang WL, Lazar A, Tseng W, Roland C, Feig B, Pollack R, Conley A, Benjamin R, Patel S, Somaiah N.. Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard. Scientific Reports 7(1). e-Pub 2017. PMID: 28928422.
30. Schvartsman G, Wagner MJ, Amini B, Zobniw CM, Trinh VA, Barbo AG, Lin HY, Wang WL, Conley AP, Ravi V, Araujo DM, Zarzour MA, Benjamin RS, Patel S, Somaiah N. Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients. Sci Rep 7(1):9519, 2017. e-Pub 2017. PMID: 28842575.
31. Groisberg R, Hong DS, Holla V, Janku F, Piha-Paul S, Ravi V, Benjamin R, Kumar Patel S, Somaiah N, Conley A, Ali SM, Schrock AB, Ross JS, Stephens PJ, Miller VA, Sen S, Herzog C, Meric-Bernstam F, Subbiah V. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. Oncotarget 8(24):39254-39267, 2017. PMID: 28424409.
32. Roszik J, Wang WL, Livingston JA, Roland CL, Ravi V, Yee C, Hwu P, Futreal A, Lazar AJ, Patel SR, Conley AP. Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes. Clin Sarcoma Res 7:11, 2017. e-Pub 2017. PMID: 28630682.
33. Groisberg R, Hong DS, Holla V, Janku F, Piha-Paul S, Ravi V, Benjamin R, Patel S, Somaiah N, Conley A, Ali S, Ross J, Stephens P, Miller V, Sen S, Herzog CE, Meric-Bernstam F, Subbiah V. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. Oncotarget 8(24), 2017. PMID: 28424409.
34. Qin Y, Conley AP, Grimm EA, Roszik J. A tool for discovering drug sensitivity and gene expression associations in cancer cells. PLoS One 12(4):e0176763, 2017. e-Pub 2017. PMID: 28453553.
35. Quintana RA, Banchs J, Gupta R, Lin HY, Raj SD, Conley A, Ravi V, Araujo D, Benjamin RS, Patel S, Vadhan-Raj S, Somaiah N. Early Evidence of Cardiotoxicity and Tumor Response in Patients with Sarcomas after High Cumulative Dose Doxorubicin Given as a Continuous Infusion. Sarcoma 2017:7495914, 2017. e-Pub 2017. PMID: 29081684.
36. Nathenson MJ, Conley AP, Lin H, Fleming N, Ravi V. Treatment of Recurrent or Metastatic Uterine Adenosarcoma. Sarcoma 2017:4680273, 2017. e-Pub 2017. PMID: 29445312.
37. Nathenson MJ, Ravi V, Fleming N, Wang WL, Conley A. Uterine adenosarcoma: a review. Curr Oncol Rep 18(11):68, 2016. PMID: 27718181.
38. Livingston JA, Hess KR, Naing A, Hong DS, Patel S, Benjamin RS, Ludwig JA, Conley A, Herzog CE, Anderson P, Meric-Bernstam F, Kurzrock R, Subbiah V. Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials. Oncotarget 7(39):64421-64430, 2016. PMID: 27486883.
39. Kamali F, Wang WL, Guadagnolo BA, Fox PS, Lewis VO, Lazar AJ, Conley AP, Ravi V, Toliyat M, Ladha HS, Hobbs BP, Amini B. MRI may be used as a prognostic indicator in patients with extra-abdominal desmoid tumors. Br J Radiol 89(1058):20150308, 2016. e-Pub 2015. PMID: 26577289.
40. Guérin A, Sasane M, Keir CH, Gauthier G, Macalalad AR, Wu EQ, Conley AP. Physician Underestimation of the Risk of Gastrointestinal Stromal Tumor Recurrence After Resection. JAMA Oncol 1(6):797-805, 2015. PMID: 26204106.
41. DeVito N, Henderson E, Han G, Reed D, Bui MM, Lavey R, Robinson L, Zager JS, Gonzalez RJ, Sondak VK, Letson GD, Conley A. Clinical Characteristics and Outcomes for Solitary Fibrous Tumor (SFT): A Single Center Experience. PLoS One 10(10):e0140362, 2015. e-Pub 2015. PMID: 26469269.
42. Raj S, Bui MM, Springett G, Conley A, Lavilla-Alonso S, Zhao X, Chen D, Haysek R, Gonzalez R, Letson GD, Finkelstein SE, Chiappori AA, Gabrilovitch DI, Antonia SJ. Long-Term Clinical Responses of Neoadjuvant Dendritic Cell Infusions and Radiation in Soft Tissue Sarcoma. Sarcoma 2015:614736, 2015. e-Pub 2015. PMID: 26880867.
43. Conley AP, Guerin A, Sasane M, Gauthier G, Schwiep F, Keir CH, Wu EQ. Treatment patterns, prescribing decision drivers, and predictors of complete response following disease recurrence in gastrointestinal stromal tumor patients-a chart extract-based approach. J Gastrointest Cancer 45(4):431-40, 2014. e-Pub 2014. PMID: 24847952.
44. Conley AP, Koplin S, Caracciollo JT, Reed DR, Webber NP, Attia S. Dramatic response to pazopanib in a patient with metastatic malignant granular cell tumor. J Clin Oncol 32(32):e107-110, 2014. e-Pub 2014. PMID: 24550417.
45. de la Fuente SG, Deneve JL, Parsons CM, Zager JS, Conley AP, Gonzalez RJ. A comparison between patients with gastrointestinal stromal tumours diagnosed with isolated liver metastases and liver metastases plus sarcomatosis. HPB (Oxford) 15(9):655-60, 2013. e-Pub 2012. PMID: 23458233.
46. Jardim DL, Conley A, Subbiah V. Comprehensive characterization of malignant phyllodes tumor by whole genomic and proteomic analysis: biological implications for targeted therapy opportunities. Orphanet J Rare Dis 8(1):112, 2013. e-Pub 2013. PMID: 23895135.
47. Conley AP, Guérin A, Sasane M, Gauthier G, Schwiep F, Keir CH, Wu EQ. Comparison of the long-term risk of recurrence and other clinical outcomes in GIST patients receiving imatinib as adjuvant therapy--a retrospective chart extract-based approach. J Gastrointest Cancer 44(2):190-8, 2013. PMID: 23229801.
48. Park MS, Ravi V, Conley A, Patel SR, Trent JC, Lev DC, Lazar AJ, Wang WL, Benjamin RS, Araujo DM. The role of chemotherapy in advanced solitary fibrous tumors: a retrospective analysis. Clin Sarcoma Res 3(1):7, 2013. e-Pub 2013. PMID: 23663788.
49. Vohra NA, Turaga KK, Gonzalez RJ, Conley A, Reed D, Bui MM, Cheong D, Letson DG, Zager JS. A single institution experience with the use of isolated limb infusion for limb salvage in limb threatening extremity sarcomas. Int J Hyperthermia 29(1):1-7, 2013. e-Pub 2012. PMID: 23205633.
50. Amankwah EK, Conley AP, Reed DR. Epidemiology and therapies for metastatic sarcoma. Clin Epidemiol 5(1):147-62, 2013. e-Pub 2013. PMID: 23700373.
51. Deneve JL, Choi J, Gonzalez RJ, Conley AP, Stewart S, Han D, Werner P, Chaudhry TA, Zager JS. Chemosaturation with percutaneous hepatic perfusion for unresectable isolated hepatic metastases from sarcoma. Cardiovasc Intervent Radiol 35(6):1480-7, 2012. e-Pub 2012. PMID: 22699779.
52. Finkelstein SE, Fishman M, Conley AP, Gabrilovich D, Antonia S, Chiappori A. Cellular immunotherapy for soft tissue sarcomas. Immunotherapy 4(3):283-90, 2012. PMID: 22401634.
53. Reynoso D, Nolden LK, Yang D, Dumont SN, Conley AP, Zhou K, Wang WL, Duensing A, Trent J. Synergistic Induction of Apoptosis by the Bcl-2 Inhibitor ABT-737 and Imatinib Mesylate in Gastrointestinal Stromal Tumor Cells. Mol Oncol 5(1):93-104, 2011.
54. Dayyani F, Conley AP, Strom SS, Stevenson W, Cortes JE, Borthakur G, Faderl S, O'Brien S, Pierce S, Kantarjian H, Garcia-Manero G. Cause of death in patients with lower-risk myelodysplastic syndrome. Cancer 116(9):2174-9, 2010. PMID: 20162709.
55. Wang WL, Conley AP, Reynoso D, Nolden LK, Lazar A, George S, Trent J. Mechanisms of Resistance to Imatinib and Sunitinib in Gastrointestinal Stromal Tumor. Cancer Chemother Pharmacol 67:S15-24. e-Pub 2010.
56. Conley AP, Trent J, Zhang W. Recent progress in the genomics of soft tissue sarcomas. Curr Opin Oncol 20(4):395-9, 2008. PMID: 18525334.

Invited Articles

1. Nathenson MJ, Conley AP. Prognostic factors for uterine adenosarcoma: a review. Expert Rev Anticancer Ther 18(11):1-8, 2018. e-Pub 2018. PMID: 30169984.
2. El Beaino M, Roszik J, Livingston JA, Wang WL, Lazar AJ, Amini B, Subbiah V, Lewis V, Conley AP. Mesenchymal Chondrosarcoma: a Review with Emphasis on its Fusion-Driven Biology. Curr Oncol Rep 20(5):37, 2018. e-Pub 2018. PMID: 29582189.
3. Conley AP, Benjamin RS. Historic Perspective and Impact of GIST: A Model for Personalized Cancer. Cancer Foundations of Clinical Cancer Research 9(1):24-26, 2010.
4. Conley AP, Stevenson W, Garcia-Manero G. Review of the Response Criteria for Myelodysplastic Syndrome. European Haematology:30-31, 2007.

Manuals, Teaching Aids, Other Teaching Publications

1. Oncology Collaborator. Personalized Cancer Therapy Website: UT MD Anderson Cancer Center, Houston, 2014.

Abstracts

1. Groisberg R, Hong D, Holla V, Janku F, Piha-Paul S, Ravi S, Benjamin R. Patel S, Somaiah N, Conley A, Ali Siraj, Schrock A, Ross J, Stephens P, Miller V, Sen S. Herzog C, Meric-Bernstam F, Subbiah V. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. Ann Oncol, 2020.
2. Conley AP. Patient-reported Outcomes (PROs) From Patients (Pts) with NTRK Fusion-Positive (NTRK-fp) Solid Tumours Receiving Entrectinib in the Global Phase 2 STARTRK-2 Study. ESMO Congress 2020, 2020.
3. Parkes AM, Patel S, Leung CH, Lin HY, Conley AP, Somaiah N, Araujo DM, Zarzour MA, Livingston JA, Ravi V, Benjamin RS, Ratan R. Systemic therapy regimen outcomes in metastatic phyllodes tumors of the breast. J. Clin Oncol 36, 2018.
4. Groisberg R, Hess KR, Hong DS, Heymach J, Naing A, Piha-Paul SA, Janku F, Javle MM, I-Nan Hu M, Conley AP, Meric-Bernstam F, and Subbiah, V. Outcomes of patients with gene fusion driven cancers treated on early phase clinical trials. Journal of Clinical Oncology 36(15), 2018.
5. Conley AP, Livingston JA, Ravi V, Shaw KR, Subbiah V, Janku F, Broaddus R, Lewis V, Patel S, Benjamin R, Wang WL, Lazar A, Futreal A, Meric-Bernstam F, Roszik J. Assessment of next generation sequencing (NGS) for patients with chondrosarcoma. CTOS 2017 Annual Meeting, 2017.
6. Roszik J, Subbiah V, Livingston JA, Somaiah N, Ravi V, Wang WL, Yee C, Futreal PA, Lazar A, Conley AP. Next generation sequencing identifies immunotherapy targets in soft tissue sarcoma. CTOS 2017 Annual Meeting, 2017.
7. Somaiah N, Conley A, Espiridion BS, Lin H, Amini B, Ravi V, Araujo D, Benjamin R, Patel S, Zarzour A, Sabir S, Lazar AJ, Wang WL, Wistuba II, Hwu P. A phase II multi-arm study to test the efficacy of durvalumab and tremelimumab in multiple sarcoma subtypes. CTOS 2017 Annual Meeting, 2017.
8. Janku F, De Groot JF, Javle MM, Pena-Prado M, Shroff RT, Luthra R, Banks K, Lanman RB, Conley AP, Broaddus R, Davies MA, Kopetz S, Yung WKA, Heymach J, Fu S, Shaw KR, Meric-Bernstam F. Simultaneous molecular alterations in solid tumors with IDH1 or IDH2 mutations. Journal of Clinical Oncology 35, 2017.
9. Livingston JA, Posey K, Subbiah V, Daw JC, Somaiah N, Ravi V, Patel S, Benjamin RS, Wang WL, Lazar A, Broaddus R, Meric-Bernstam F, Shaw KR, Roszik J, Conley AP. Analysis of osteosarcoma subtypes by clinical genomic testing to identify clinically actionable alterations. Journal of Clincal Oncology:35, 2017.
10. Nathenson M, Conley AP, Ratan R, Zarzour MA, Somaiah N, Araujo DM, Patel S, Benjamin RS, Ravi V. Efficacy of front-line chemotherapy for recurrent/metastatic adenosarcoma of the uterus. J Clin Oncol, 2016.
11. Conley AP, Huh WW, Roszik J, Harrison DJ, Hayes-Jordan AA, Kehr KA, Ratan R, Ravi V, Arauo DM, Zarzour MA, Ludwig JA, Wang WL, Benjamin RS, Patel S. Clinical characteristics of adult alveolar rhabdomyosarcoma (ARMS) patients (Pts) on front-line therapies: An MD Anderson Cancer Center (MDACC) series. J Clin Oncol, 2016.
12. Roszik J, Wang WL, Ravi V, Hwu P, Yee C, Futreal A, Lazar A, Conley AP. Expression and clinical correlations of PRAME in sarcoma subtypes. J Clin Oncol, 2016.
13. Groisberg R, Hong DS, Janku F, Piha-Paul SA, RAvi V, Benjamin RS, Patel S, Somaiah N, COnley AP, Herzog CE, Meric-Bernstam F, Subbiah V. Clinical next generation sequencing in sarcomas. J Clin Oncol, 2016.
14. Somaiah N, Berid H, Shaw KR, Wang WL, Conley AP, Ravi V, Torress KE, Ingram D, Roland CL, Subbiah V, Feig BW, Lazar AJF, Benjamin RS, Patel S, Hwu P, Futreal A, Meric-Bernstam F, Hong DS. Targeted next generation sequencing in well-differentiated/dedifferentiated liposrcoma (WD/DD LPS): Multiple gene amplifications but few mutations. J Clin Oncol, 2015.
15. Conley AP, Satcher Rl, Wang WL, Lazar AJF, Fox PS, Lin PP, Moon B, Bird JE, Araujo DM, Ravi V, Somaiah N, Patel S, Benjamin RS, Lewis VO. Clinical Characteristics and treatment outcomes of clear cell chondrosarcomas: MD Anderson Cancer Center Series. J Clin Oncol, 2015.
16. Subbiah V, Murthy R, Hong D, Brown RE, Prins R, HOsing C, McGuire M, Naing A, Fu S, Chou T, Lin Q, Guevarra RP, COnley A, Kaur I, Meric-Bernstam F, Bosch M. Clinical and immunopathological effects following image-guided intratumoral injection of activated, autologous dendritic cells in patients with advanced solid cancers. Cancer Research 75, 2015.
17. Subbiah V, Murthy R, Hong D, Prins R, Hosing C, Brown R, McGuire M, Naing A, Fu S, Conley A, Kaur I, Hendricks K, Kolli D, Noffsinger L, Bosch M. Safety, feasibility, and functionality of activated autologous dendritic cells for intratumoral injection in solid tumors: a Phase I clinical trial. Journal fo ImmunoTherapy of Cancer:199, 2015.
18. Vadhan-Raj S, Ravi V, Zhou X, Araujo DM, Somaiah N, Conley AP, Daniel M, Benjamin RS, Patel S, Spasojevic I. Effects of fosaprepitan (Fosa) on ifosfamide (Ifex) metabolism in sarcoma patients (pts) receiving multi-day chemotherapy (CT) regimen on doxorubicin (Dox) and Ifex (AI): Randomized, cross-over study. J Clin Oncol, 2015.
19. Conley AP, Sasane M, Pelletier CL, Guerin A, Macalalad AR, Huang Q, Wu EQ. Assessment and management o the risk of recurrence of resected astrointestinal stromal tumors. J Clin Oncol, 2014.
20. Subbiah V, Agarwal R, Janku F, Tsimberidou AM, Patel S, Benjamin RS, Ludwig HA, Anderson PM, Araujo DM, Ravi V, Conley AP Somaiah N, Wang WL, Naing A, Zinner R, Hong DS, Meric-Bernstam F. Diversity and heterogeneity in molecular analysis of advanced sarcomas: the clinical, regulatory, and financial challenge for drug development and precision medicine. J Clin Oncol, 2014.
21. Somaiah N, Gomez DBD, Madewell JE, Wang WL, Conley AP, Ravi V, Araujo DM, Ludwig JA, Benjamin RS, Patel S. Defining the chemotherapy (CT) response in well-differentiated CT response in well-differentiated (WD) and dedifferentiated (DD) liposarcomas (LPS) of the etroperitoneum (RP): A tertiary referral cancer center experience. J Clin Oncol, 2014.
22. Raj SKS, Indelicato DJ, Chiappori A, COnley AP, Gonzales R, Heysec R, Letson DD, Gabrilovich D, Bui MM, Finkelstein S, Antonia SJ. Neoadjuvant administration of radiation therapy and intratumoral autologous dendritic cells in patients with localized high-risk soft tissue sarcomas. J Clin Oncol, 2014.
23. Ravi V, Ramesh N, Patnana M, Conley AP, Somaiah N, Zarzour MA, Ingram D, Little L, Protopopov A, Lazar AJF, Araujo DM, Tores KE, Patel S, Zhang J, Ali SM, Miller VA, Stephens PJ, Benjamin RS, Hwu P, Futreal A. Whole-exome and targeted sequencing of angiosarcomas: target identification and treatments implications. J Cllin Oncol, 2014.
24. Vadhan-Raj S, Zhou X, Araujo DM, Somaiah N, Conley AP, Ravi V, Daniel M, Benjamin RS, Patel S. Effects of fosaprepitant (Fosa) administered as single dose versus two doses, on nausea/vomiting (N/V) in patients receivig multiday chemotherapy (CT) with a highly emetogenic regimen of doxorubicin and ifosfamide (AI): randomized cross-over study. J Clin Oncol, 2014.
25. Somaiah N, Pollack SM, Wei W, Araujo D, Amaria RN, Mittendorf EA, Conley AP, Ravi V, Subbiah V, Benjamin RS, Patel S, Kenney R, Hsu F, Hwu P, Jones RL, Shapiro G, Kim JW, Block MM. Evaluating the safety and immunogenicity of ID-LV305, a third generation lentiviral vaccine in patients with NY-ESO-1 positive malignancies. CTOS 2014 Annual Meeting, 2014.
26. Subbiah V, Patel S, Benjamin RS, Agarwal R, Janku F, Ludwig J, Anderson PM, Arujo D, Ravi V, Conley AP, Somaiah N, Naing A, Hong DS, Maric-Bernstam F. Target-based therapeutic matching in early-phase clinical trials in patients with advanced sarcoma. CTOS 2014 Annual Meeting, 2014.
27. Livingston JA, Bugano D, Madewell J, Wang WL, Conley AP, RAvi V, Araujo D, Tsen WW, Feig B, Toress KE, Benjamin RS, Patel S, Somaiah N. Assessing chemotherapy benefit in well-differentiated/de-differentiated liposarcoma. CTOS 2014 Annual Meeting, 2014.
28. Ravi V, Ramesh N, Conley AP, Somaiah N, Subbiah V, Lazar A, Benjamin RS, Patel S. Prediciting survival usi FDG-PET responses in patients with unclassified sarcoma. CTOS 2014 Annual Meeting, 2014.
29. Conley AP, Wang WL, Ravi V, Somaiah N, Subbiah V, Lazar A, Benjamin RS, Patel S. Clinical outcomes for patients with metastatic, malignant granular cell tumors treated with systemic therapies. CTOS 2014 Annual Meeting, 2014.
30. Guerin A, Sasane M, Keir C, Gauthier G, Macalalad A, Wu E, Conley AP.. Association between risk of recurrence assessment and adjuvant treatment (Tx) duration in patients (pts) with resected gastrointestinal stromal tumor. Annals of Oncology, 2014.
31. Conley AP, Guerin A, Sasane M, Gautheir G, Schwiep FA, Keir CH, Magestro M, Wu EQ. Predictors of complete response following disease recurrence in gastrointestinal stromal tumor (GIST) patient: A retrospective patient chart review analysis. J Clin Oncol, 2013.
32. Dalia S, Conley AP, Fisher K, Lee JH, Wehham RM, Apte S, Gonzalez RJ. Clinicopathologic predictors (CP) of survival in patients with endometrial stromal sarcomas (ESS) treated with multimodality therapy. J Clin Oncol, 2013.
33. Guerin A, Sasane M, Gauthier G, Schwiep FA, Keir CH, Magestro M, Wu EQ, Conley AP. Prescribing decision drivers in patients with recurrent gastrointestinal stromal tulor (GIST) previoulsy treated with adjuvant imatinib: A retrospective chart extract-based approach. J Clin Oncol, 2013.
34. Gauthier G, Sasane M, Guerin A, Schwiep FA, Keir CH, Magestro M, Wu EQ, Conley AP. Tumor characteristics and treatment (trt) patterns following disease recurrence in gastrointestinal stromal tumor (GIST) patients (pts) who received adjuvant imatinib (IM) as primary trt: A retrospective chart extract based approach. J Clin Oncol, 2013.
35. Jones RL, Berry DA, Chawla SP, Chmeilowski B, Wagner A, Patel Sm, COnley AP, Reed D, Shin CR, Weil SC, Heyburn J, Schulert L, Hulstine AM, Maki RG. Part 1 of a multicenter, two-part, phase II study of the safety and efficacy of the combination of gemcitabine and docetaxel with MORAB-004 in metastatic soft tissue sarcoma. CTOS 2013 Annual Meeting, 2013.

Book Chapters

1. Subbiah V, Roszik J, Conley A.. In: Handbook of Targeted Cancer Therapy and Immunotherapy. Wolters Kluwer: Philadelphia, PA, 2018.
2. Conley AP, Ravi V, Patel S.. Targeted Therapy in Solid Tumors: Sarcomas. In: Targeted Therapy in Translational in Cancer Research. John Wiley & Sons, Inc: New York, 2016.
3. Livingston JA, Conley A, Ravi V, Patel S.. The MD Anderson Manual of Medical Oncology. In: Soft Tissue and Bone Sarcomas. Third. McGraw Hill Medical: New York, 2015.
4. Subbiah V, Conley A. In: Sarcoma Chapter. Handbook of Targeted Cancer Therapy. Philadelphia, PA: Wolters Kluwer, 2014.
5. Henderson-Jackson E, Conley A and Bui MM. Molecular Pathology of bone and soft tissue neoplasms and potential targets for novel therapy. In: Cancer Growth and Progression. In: Chapter 13. Springer: New York, 2012.
6. Conley, AP, Park MS, Trent J, Patel S. Chapter 40: Soft-Tissue and Bone Sarcomas. In: The MD Anderson Manual of Medical Oncology. McGraw Hill Medical: New York, 2010.